ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 659

Low Dose IL-2 Therapy Can Restore the Balance of Th17 and Treg Cells in Refractory Patients with Sjogren’s Syndrome

Miao Miao1, Shengxiao Zhang1, Xiao-Qing Liu1, Xiaoyan Wu2, Chong Gao3 and Xiao-Feng Li2, 1The Second Hospital of Shanxi Medical University, Taiyuan, China, 2Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, 3Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women’s Hospital/Children’s Hospital Boston, Harvard Medical School, Boston, MA, Cambridge, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Sjogren's syndrome, T-Regulatory Cells and interleukins (IL)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Sjögren's Syndrome - Poster I: Translational Science

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The therapy for sjogren’s syndrome (SS) focuses on biological agents, immune inhibitors and glucocorticoid which can’t correct the problem of unbalance of Th17 and Regulatory T (Treg) cells in refractory patients. It was reported that IL-2 had a critical effect on homeostatic maintenance of the Th17 and Treg cells and the ratio of them. The study is to explore the effect of low dose IL-2 therapy on the balance of Treg and Th17 cells in refractory patients with SS and observe the efficiency and side effects of the therapy.

Methods: SS patients (n=18) (from march 1st to may 30thin 2016, both outpatients and inpatients in our department, according to American-European Consensus Group criteria for SS) with decreased Treg cells (18/18) and increased ratio of Th17/Treg (16/18), who were refractory to standard therapy including glucocorticoid, immune-suppressants, biological agents or combination of them, were given low-dose IL-2 (50 WIU/day for 5 days) by hypodermic injection. Laboratory indicators were compared before and after IL-2 treatment. The side effects were observed in the course of therapy.

Results: The number of Treg cells significantly increased after the treatment and returned to normal range in 89% (16/18) of patients by 1 week (12.24±3.95 vs. 48.10±33.21, p<0.01). At the same time, there was a significantly decrease in the ratio of Th17/Treg cells (0.66±0.52 vs. 0.36±0.41, p<0.1), which returned to normal range in 7 patients and was lower in 14 patients. Besides, Th17 cells were also increased (8.11±6.72 vs. 12.91±10.04, p<0.1). Clinical manifestations were improved after the combitional treatment of IL-2 and traditional drugs. No obvious adverse reactions were observed.

Conclusion: Low dose IL-2 therapy can restore and maintain the balance of Th17 and Treg cells in the refractory patients with SS. Manifestation improved after the combitional therapy. The therapy is safe. More research is needed to investigate long term efficiency of the therapy and the prognosis of the patients.


Disclosure: M. Miao, None; S. Zhang, None; X. Q. Liu, None; X. Wu, None; C. Gao, None; X. F. Li, National Natural Science Foundation of China (no. 81301532/H0603) and the Shanxi Scholarship council of China (no. 2013-118), 2.

To cite this abstract in AMA style:

Miao M, Zhang S, Liu XQ, Wu X, Gao C, Li XF. Low Dose IL-2 Therapy Can Restore the Balance of Th17 and Treg Cells in Refractory Patients with Sjogren’s Syndrome [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/low-dose-il-2-therapy-can-restore-the-balance-of-th17-and-treg-cells-in-refractory-patients-with-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-dose-il-2-therapy-can-restore-the-balance-of-th17-and-treg-cells-in-refractory-patients-with-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology